TASIGNA®


CAPSULE
scheduling status
S4
registration number
45/26/0410; 41/26/0973
What TASIGNA® contains
Each capsule contains nilotinib hydrochloride monohydrate equivalent to 150 mg nilotinib base. Each capsule contains nilotinib hydrochloride monohydrate equivalent to 200 mg nilotinib base.
other ingredients
TASIGNA 150 mg capsule: Capsule content: Lactose monohydrate; Crospovidone; Poloxamer 188; Colloidal silicon dioxide; Magnesium stearate Capsule shell: Gelatin; Titanium dioxide; Iron oxide, yellow Iron oxide, red Printing ink: Iron oxide, black TASIGNA® 200 mg capsule: Capsule content: Lactose monohydrate; Crospovidone; Poloxamer 188; Colloidal silicon dioxide; Magnesium stearate Capsule shell: Gelatin; Titanium dioxide Iron oxide, yellow Printing ink: Iron oxide, red.
Therapeutic classification
L01EA03 BCR - ABL tyrosine kinase inhibitors.
© 2026 SAHPRA. ALL RIGHTS RESERVED